Actively Recruiting

Phase Not Applicable
Age: 12Years - 30Years
All Genders
NCT06886971

Strategies to AchieVe Viral Suppression for Youth With HIV

Led by Johns Hopkins University · Updated on 2026-02-04

288

Participants Needed

1

Research Sites

194 weeks

Total Duration

On this page

Sponsors

J

Johns Hopkins University

Lead Sponsor

N

National Institute of Mental Health (NIMH)

Collaborating Sponsor

AI-Summary

What this Trial Is About

Although there have been advances in antiretroviral treatment (ART) for HIV, adolescents and young adults living with HIV (AHIV) continue to have disparate HIV outcomes particularly viral suppression (VS), when compared to other populations likely related to multi-layered challenges (social determinants, cognitive development), system, and biomedical challenges including the reliance on oral ART as the only choice for HIV treatment. Given that approximately 1/3 of AHIV despite being in care fail to attain or sustain VS with resultant individual and public health risk, there is a need to develop real-world implementable interventions that can improve the participants virologic outcomes. The Strategies to AchieVe Viral Suppression for Youth with HIV (SAVVY) Study aims to 1) optimize personal ART choice by using the HIV-ASSIST clinical program to inform CHOICE counseling regarding an AHIV's preferred approach, including the possibility of long-acting injectable ART (LAI-ART); 2) facilitate access to the participants preferred choice through deploying a focused team to navigate barriers to attaining LAI-ART; and 3) decipher and address the patient, provider, and systemic barriers to the uptake and routinization of LAI-ART among AHIV by applying an implementation science framework and assessing cost-effectiveness providing critical data to support comprehensive approaches to optimizing ART and VS for AHIV, a key population identified in the Ending the HIV Epidemic in the United States Initiative.

CONDITIONS

Official Title

Strategies to AchieVe Viral Suppression for Youth With HIV

Who Can Participate

Age: 12Years - 30Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Prescribed antiretroviral therapy (ART)
  • Willing to sign informed consent, including communication with one's primary HIV provider
Not Eligible

You will not qualify if you...

  • Presence of drug resistance mutations compromising cabotegravir plus rilpivirine activity
  • Use of disallowed medications
  • Pregnancy
  • Mental health, cognitive, or behavioral dysfunction impairing participation as judged by the site PI
  • Severe illness or hospitalization at enrollment
  • Plan to move away within the next 12 months

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Johns Hopkins University

Baltimore, Maryland, United States, 21287

Actively Recruiting

Loading map...

Research Team

A

Allison Agwu, MD, SCM

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here